SCHEMBL29703

SCHEMBL29703

O=[N+]([O-])c1ccc2c(ccn2C2O[C@H](CO)[C@@H](O)[C@H]2O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
THRB P10828 1/20 0.49
MTOR P42345 1/20 0.49
MDM2 Q00987 1/20 0.49
NCOA1 Q15788 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
SLC29A1 Q99808 9/20 0.48
SLC28A1 O00337 1/20 0.48
SLC28A2 O43868 1/20 0.48
SLC28A3 Q9HAS3 1/20 0.48
ADORA3 P0DMS8 1/20 0.47
CYP1A2 P05177 1/20 0.47
NFKB1 P19838 1/20 0.47
THPO P40225 1/20 0.47
ALDH1A1 P00352 1/20 0.47
PMP22 Q01453 1/20 0.47
RAB9A P51151 1/20 0.46
CYP3A4 P08684 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1062447 1.00 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL14084325 1.00 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL29446054 1.00 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL14534827 1.00 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL1372596 0.92 LMNA (0.48) LMNATHRBMTORMDM2NCOA1
SCHEMBL30356 0.92 LMNA (0.48) LMNATHRBMTORMDM2NCOA1
SCHEMBL11934656 0.91 SLC29A1 (0.42) LMNATHRBMTORMDM2NCOA1
SCHEMBL11934657 0.91 SLC29A1 (0.42) LMNATHRBMTORMDM2NCOA1
SCHEMBL650683 0.87 CYP1A2 (0.42) SLC29A1ADORA3CYP1A2NFKB1THPO
SCHEMBL11934658 0.84 SLC29A1 (0.39) LMNASLC29A1RAB9ACYP3A4PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007030167-A1 MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES NASTECH PHARMACEUTICAL COMPANY INC. (US) 2007-03-15 WO claimed
WO-2025054459-A1 RNAI OLIGONUCLEOTIDE CONJUGATES DICERNA PHARMACEUTICALS, INC. (US) 2025-03-13 WO disclosed
WO-2025029625-A1 COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION DICERNA PHARMACEUTICALS, INC. (US) 2025-02-06 WO disclosed
WO-2024208249-A1 NUCLEOSIDE ANALOG FOR 5'-PHOSPHONATE MODIFICATION AND OLIGONUCLEOTIDE PREPARED THEREFROM 上海舶望制药有限公司 2024-10-10 WO disclosed
EP-4441218-A2 COMPOSITIONS AND METHODS FOR MODULATING APOC3 EXPRESSION Dicerna Pharmaceuticals, Inc. (US) 2024-10-09 EP disclosed
EP-4323518-A2 COMPOSITIONS AND METHODS FOR INHIBITING KETOHEXOKINASE (KHK) Boehringer Ingelheim International GmbH (DE) 2024-02-21 EP disclosed
EP-4323519-A1 COMPOSITIONS AND METHODS FOR MODULATING PNPLA3 EXPRESSION Dicerna Pharmaceuticals, Inc. (US) 2024-02-21 EP disclosed
US-20230250435-A1 PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS DICERNA PHARMACEUTICALS, INC. 2023-08-10 US disclosed
WO-2023141247-A2 COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B ALEXION PHARMACEUTICALS, INC. (US) 2023-07-27 WO disclosed
EP-4192505-A1 SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES Dicerna Pharmaceuticals, Inc. (US) 2023-06-14 EP disclosed
WO-2008109500-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING PRKCA GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008109547-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING TYMP GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008109353-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING MAP2K GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008109354-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING IL18 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008109526-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING EGR GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008109520-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING CXC GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008109518-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING WNT GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008109487-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING MME GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 WO disclosed
WO-2008022046-A2 DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS NASTECH PHARMACEUTICAL COMPANY INC. (US) 2008-02-21 WO disclosed
WO-2007030167-A1 MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES NASTECH PHARMACEUTICAL COMPANY INC. (US) 2007-03-15 WO disclosed